Sales 2024 * | 181M 247M | Sales 2025 * | 249M 338M | Capitalization | 593M 807M |
---|---|---|---|---|---|
Net income 2024 * | -19M -25.86M | Net income 2025 * | 21M 28.58M | EV / Sales 2024 * | 3.27 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.38 x |
P/E ratio 2024 * |
-30.8
x | P/E ratio 2025 * |
29.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.92% |
Latest transcript on Imprimis Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Andrew Boll
DFI | Director of Finance/CFO | 41 | 11-11-30 |
Jamie Webb
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Baum
CEO | Chief Executive Officer | 51 | 05-12-31 |
Director/Board Member | 65 | 01-25 | |
Adrienne Graves
BRD | Director/Board Member | 69 | 01-25 |
1st Jan change | Capi. | |
---|---|---|
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |